CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

Rhea-AI Summary

Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.

CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.

Positive

• Secured long-term manufacturing partnership for commercial supply of VK2735
• Multiple formulation options (both injectable and oral) increase market potential
• Manufacturing redundancy through multiple sites reduces supply chain risks

Negative

• Dependency on single manufacturing partner for entire supply chain

News Market Reaction

-5.15%

1 alert

-5.15% News Effect

On the day this news was published, VKTX declined 5.15%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

• CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.
  
  
• CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.
  
  
• CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.

BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders. Under this multi-year supply contract, CordenPharma provides development and manufacturing services for clinical and commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735, a Dual GLP-1/GIP Receptor Agonist, across the full supply chain from drug substance to drug product for both its subcutaneous and oral peptide formulations.

CordenPharma & Viking Therapeutics sign long-term integrated supply partnership to support GLP-1 drug candidate VK2735.

CordenPharma is committed to ensuring seamless development and commercialization of Viking Therapeutics' VK2735 drug candidate by leveraging its global network of advanced manufacturing facilities for drug substance, fill-finish and oral solid dosage finished product.

This uniquely integrated capability incorporates CordenPharma's extensive experience in large-scale peptide drug substance, sterile injectable fill-finish, and oral solid dosage manufacturing. With built-in redundancy through multiple drug substance sites across its global facility network, CordenPharma is well-positioned to ensure a secure and uninterrupted supply chain throughout the lifecycle of Viking Therapeutics' VK2735 drug candidate.

Dr. Michael Quirmbach, President & CEO of the CordenPharma Group, comments: "We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for this innovative VK2735 drug candidate. Our global teams are excited to provide true integration of our expertise across the pharma supply chain to meet the increasing demand for GLP-1 peptide therapeutics and ultimately, improve patient outcomes."

About CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2024 financial year, the organization generated sales of €854 million and had over 3,000 employees. In 2022, CordenPharma was acquired by Astorg - a leading Pan-European private equity firm with deep expertise in the healthcare sector - to accelerate its development and further strengthen its leadership in the CDMO peptide space.

Please visit cordenpharma.com for more information I Follow CordenPharma on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cordenpharma-and-viking-therapeutics-sign-long-term-strategic-partnership-for-integrated-supply-of-glp-1-peptides-injectables-and-oral-formulations-302397563.html

SOURCE CordenPharma

FAQ

What is the scope of Viking Therapeutics' (VKTX) partnership with CordenPharma for VK2735?

The partnership covers end-to-end manufacturing services for VK2735, including drug substance production, fill-finish for subcutaneous formulation, and oral solid dosage manufacturing.

How will CordenPharma ensure reliable supply of Viking's (VKTX) VK2735 drug candidate?

CordenPharma has built-in redundancy through multiple drug substance sites across its global facility network to ensure uninterrupted supply.

What formulations of VK2735 will CordenPharma manufacture for Viking Therapeutics (VKTX)?

CordenPharma will manufacture both subcutaneous injectable and oral peptide formulations of VK2735.

What type of drug is Viking Therapeutics' (VKTX) VK2735?

VK2735 is a Dual GLP-1/GIP Receptor Agonist drug candidate for metabolic and endocrine disorders.